Advertisement

Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure

Published:November 20, 2009DOI:https://doi.org/10.1016/j.yjmcc.2009.10.025

      Abstract

      Animal studies suggest that the endocannabinoid system (ECS) plays a role in the regulation of myocardial contractility and in the pathogenesis of heart failure. The current study aimed to proof the existence of endocannabinoid receptors on human ventricular myocardium and to determine whether human chronic heart failure (CHF) is associated with changes in endocannabinoid receptor expression and distribution. Expression of cannabinoid receptor 1 (CB1) and cannabinoid receptor (CB2) on human heart was assessed by means of real-time PCR and immunohistochemistry. On healthy human left ventricular myocardium, mRNA transcripts of CB1 and CB2 receptors were expressed in an almost equal proportion. In patients with CHF, mRNA expression of CB1 receptors was shown to be downregulated 0.7-fold (0.7.±0.15, n=12, p<0.01), whereas expression of CB2 receptors was upregulated more than 11-fold (11.6±4.5; n=12; p<0.005). Corresponding results were obtained by immunohistochemistry. Blood levels of endocannabinoids were significantly elevated (anandamide 3.5-fold (p<0.001); 2-AG 7-fold (p=0.02)) in patients with CHF, as compared to healthy volunteers. Both CB1 and CB2 receptors are present on healthy human left ventricular myocardium in a balanced distribution. Patients suffering from CHF exhibit a shift of the CB1–CB2 receptor ratio towards expression of CB2 receptors combined with significantly elevated peripheral blood levels of endocannabinoids indicating an activation of the ECS. These results might open up new perspectives regarding the role of endocannabinoid signalling in CHF and its potential as a target for pharmacological modulation.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Jessup M.
        • Brozena S.
        Heart failure.
        N. Engl. J. Med. 2003 May 15; 348: 2007-2018
        • Hunt S.A.
        • Baker D.W.
        • Chin M.H.
        • Cinquegrani M.P.
        • Feldman A.M.
        • Francis G.S.
        • et al.
        ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America.
        Circulation. 2001 Dec 11; 104: 2996-3007
        • Redfield M.M.
        Heart failure—an epidemic of uncertain proportions.
        N. Engl. J. Med. 2002 Oct 31; 347: 1442-1444
        • Liao L.
        • Anstrom K.J.
        • Gottdiener J.S.
        • Pappas P.A.
        • Whellan D.J.
        • Kitzman D.W.
        • et al.
        Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study.
        Am. Heart J. 2007 Feb; 153: 245-252
        • De Petrocellis L.
        • Di Marzo V.
        An introduction to the endocannabinoid system: from the early to the latest concepts.
        Best Pract Res Clin Endocrinol Metab. 2009 Feb; 23: 1-15
        • Di Marzo V.
        Targeting the endocannabinoid system: to enhance or reduce?.
        Nat Rev Drug Discov. 2008 May; 7: 438-455
        • Sugamura K.
        • Sugiyama S.
        • Nozaki T.
        • Matsuzawa Y.
        • Izumiya Y.
        • Miyata K.
        • et al.
        Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages.
        Circulation. 2009 Jan 6; 119: 28-36
        • Di Marzo V.
        Endocannabinoids: synthesis and degradation.
        Rev Physiol Biochem Pharmacol. 2008; 160: 1-24
        • Hiley C.R.
        Endocannabinoids and the heart.
        J. Cardiovasc. Pharmacol. 2009 Apr; 53: 267-276
        • Hiley C.R.
        • Ford W.R.
        Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling.
        Biol. Rev. Camb. Philos. Soc. 2004 Feb; 79: 187-205
        • Sterin-Borda L.
        • Del Zar C.F.
        • Borda E.
        Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways.
        Biochem. Pharmacol. 2005 Jun 15; 69: 1705-1713
        • Bonz A.
        • Laser M.
        • Kullmer S.
        • Kniesch S.
        • Babin-Ebell J.
        • Popp V.
        • et al.
        Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle.
        J. Cardiovasc. Pharmacol. 2003 Apr; 41: 657-664
        • Batkai S.
        • Mukhopadhyay P.
        • Harvey-White J.
        • Kechrid R.
        • Pacher P.
        • Kunos G.
        Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats.
        Am. J. Physiol. Heart Circ. Physiol. 2007 Sep; 293: H1689-H1695
        • Mukhopadhyay P.
        • Batkai S.
        • Rajesh M.
        • Czifra N.
        • Harvey-White J.
        • Hasko G.
        • et al.
        Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.
        J. Am. Coll. Cardiol. 2007 Aug 7; 50: 528-536
        • Currie S.
        • Rainbow R.D.
        • Ewart M.
        • Kitson S.
        • Pliego E.H.
        • Kane K.A.
        • et al.
        IP3R-mediated Calcium release is modulated by anadamide in isolated cardiac nuclei.
        J. Mol. Cell Cardiol. 2008; 45: 804-811
        • Schmidt A.
        • Brune K.
        • Hinz B.
        Determination of the endocannabinoid anandamide in human plasma by high-performance liquid chromatography.
        Biomed. Chromatogr. 2006 Apr; 20: 336-342
        • Vogeser M.
        • Hauer D.
        • Christina A.S.
        • Huber E.
        • Storr M.
        • Schelling G.
        Release of anandamide from blood cells.
        Clin. Chem. Lab. Med. 2006; 44: 488-491
        • Schelling G.
        • Hauer D.
        • Azad S.C.
        • Schmoelz M.
        • Chouker A.
        • Schmidt M.
        • et al.
        Effect of general anesthesia on anandamide blood levels in humans.
        Anesthesiology. 2006; 104: 273-277
        • Vogeser M.
        • Schelling G.
        Pitfalls in measuring the endocannabinoid 2-arachidonoyl glycerol in biological samples.
        Clin. Chem. Lab. Med. 2007; 45: 1023-1025
        • Pfaffl M.W.
        A new mathematical model for relative quantification in real-time RT-PCR.
        Nucleic Acids Res. 2001 May 1; 29: e45
        • Vandesompele J.
        • De P.K.
        • Pattyn F.
        • Poppe B.
        • Van R.N.
        • De P.A.
        • et al.
        Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.
        Genome Biol. 2002 Jun 18; 3 (RESEARCH0034)
        • Perez S.
        • Royo L.J.
        • Astudillo A.
        • Escudero D.
        • Alvarez F.
        • Rodriguez A.
        • et al.
        Identifying the most suitable endogenous control for determining gene expression in hearts from organ donors.
        BMC Mol. Biol. 2007; 8: 114
        • Lepicier P.
        • Bibeau-Poirier A.
        • Lagneux C.
        • Servant M.J.
        • Lamontagne D.
        Signaling pathways involved in the cardioprotective effects of cannabinoids.
        J. Pharmacol. Sci. 2006 Oct; 102: 155-166
        • Lepicier P.
        • Lagneux C.
        • Sirois M.G.
        • Lamontagne D.
        Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts.
        Life Sci. 2007 Oct 13; 81: 1373-1380
      1. Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J 2009 Jul;23(7):2120–30.

        • Marchese A.
        • Paing M.M.
        • Temple B.R.
        • Trejo J.
        G protein-coupled receptor sorting to endosomes and lysosomes.
        Annu. Rev. Pharmacol. Toxicol. 2008; 48: 601-629
        • Wagner J.A.
        • Hu K.
        • Karcher J.
        • Bauersachs J.
        • Schafer A.
        • Laser M.
        • et al.
        CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction.
        Br. J. Pharmacol. 2003 Apr; 138: 1251-1258
        • Mackie K.
        Cannabinoid receptors: where they are and what they do.
        J. Neuroendocrinol. 2008 May; 20: 10-14
        • Zaugg M.
        • Schaub M.C.
        Cellular mechanisms in sympatho-modulation of the heart.
        Br. J. Anaesth. 2004 Jul; 93: 34-52
        • Malysz J.
        • Daza A.V.
        • Kage K.
        • Grayson G.K.
        • Yao B.B.
        • Meyer M.D.
        • et al.
        Characterization of human cannabinoid CB2 receptor coupled to chimeric Galpha(qi5) and Galpha(qo5) proteins.
        Eur. J. Pharmacol. 2009 Jan 28; 603: 12-21
        • Qvigstad E.
        • Sjaastad I.
        • Brattelid T.
        • Nunn C.
        • Swift F.
        • Birkeland J.A.
        • et al.
        Dual serotonergic regulation of ventricular contractile force through 5-HT2A and 5-HT4 receptors induced in the acute failing heart.
        Circ Res. 2005 Aug 5; 97: 268-276
        • Sjaastad I.
        • Schiander I.
        • Sjetnan A.
        • Qvigstad E.
        • Bokenes J.
        • Sandnes D.
        • et al.
        Increased contribution of alpha 1- vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure.
        Acta Physiol. Scand. 2003 Apr; 177: 449-458
        • Wild D.M.
        • Kukin M.
        Beta-blockers to prevent symptomatic heart failure in patients with stage A and B heart failure.
        Curr. Heart Fail. Report. 2007; 4: 99-102
        • Ford W.R.
        • Honan S.A.
        • White R.
        • Hiley C.R.
        Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts.
        Br. J. Pharmacol. 2002 Mar; 135: 1191-1198
        • Dhalla N.S.
        • Saini H.K.
        • Tappia P.S.
        • Sethi R.
        • Mengi S.A.
        • Gupta S.K.
        Potential role and mechansims of remodeling in cardiac dysfunction due to ischemic heart disease.
        J. Cardiovasc. Med. (Hagerstown). 2007; 8: 238-250
        • Lim S.Y.
        • Davidson S.M.
        • Yellon D.M.
        • Smith C.C.
        The cannabinoid CB(1) receptor antagonist, rimonabant, protects against acute myocardial infarction.
        Basic Res. Cardiol. 2009 May 22;
        • Varga K.
        • Wagner J.A.
        • Bridgen D.T.
        • Kunos G.
        Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension.
        FASEB J. 1998 Aug; 12: 1035-1044
        • Yndestad A.
        • Damas J.K.
        • Oie E.
        • Ueland T.
        • Gullestad L.
        • Aukrust P.
        Systemic inflammation in heart failure–the whys and wherefores.
        Heart Fail. Rev. 2006 Mar; 11: 83-92
        • Godlewski G.
        • Offertaler L.
        • Wagner J.A.
        • Kunos G.
        Receptors for acylethanolamides-GPR55 and GPR119.
        Prostaglandins Other Lipid Mediat. 2009 Sep; 89: 105-111
        • Ross R.A.
        The enigmatic pharmacology of GPR55.
        Trends Pharmacol. Sci. 2009 Mar; 30: 156-163
        • Jarai Z.
        • Wagner J.A.
        • Varga K.
        • Lake K.D.
        • Compton D.R.
        • Martin B.R.
        • et al.
        Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
        Proc. Natl. Acad. Sci. U. S. A. 1999 Nov 23; 96: 14136-14141